<DOC>
	<DOCNO>NCT01328158</DOCNO>
	<brief_summary>This study Kaletra ( Lopinavir ( LPV ) /Ritonavir ( RTV ) ) tablet conduct clarify follow regard treatment drug : 1 . Incidence condition occurrence adverse reaction clinical set 2 . Factors may affect safety effectiveness Kaletra ( QD )</brief_summary>
	<brief_title>Drug Use Investigation Kaletra Tablets ( Once Daily Administration ) Patients With HIV-infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Participants receive Kaletra start Kaletra therapy registration period . Participants history hypersensitivity ingredient drug . Participants undergo treatment follow drug : pimozide , ergotamine tartrate , dihydroergotamine mesilate , ergometrine maleate , methylergometrine maleate , midazolam , triazolam , vardenafil hydrochloride hydrate , sildenafil citrate ( Revatio ) , tadalafil ( Adcirca ) , blonanserin , azelnidipine , rivaroxaban , voriconazole .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Kaletra , Lopinavir ( LPV ) /Ritonavir ( RTV ) , Human Immunodeficiency Virus ( HIV ) infection</keyword>
</DOC>